Diffuse tenosynovial giant cell tumor

Last revised by Magdi Mahsoub on 29 Mar 2025

Diffuse tenosynovial giant cell tumor, previously known as pigmented villonodular synovitis (PVNS), is an uncommon benign condition. It is most commonly monoarticular (~70% in the knee joint), but can occasionally be polyarticular. 

Please see the overview article tenosynovial giant cell tumor for content common to both the localized type and diffuse type.

Diffuse tenosynovial giant tumors occur predominantly in early middle age (<40 years) 1,2,11. In intra-articular disease, there is no gender predilection, whereas extra-articular disease has a slight female predominance ref.

Presentation usually involves joint swelling, pain and reduced range of motion 11. Hemarthrosis is common 11. Symptoms are usually present for many months or years before the diagnosis is made.

Although unusual in the pediatric population, it is sometimes seen and is more frequently polyarticular. It has also been described in association with 2:

Typically, diffuse tenosynovial giant cell tumors are monoarticular and joints with large synovial surfaces are predictably most frequently affected with the knee being the most frequently affected (~75%) followed by the hip (~10%), ankle, shoulder, elbow, facet joints, and rarely other joints (e.g. temporomandibular joint) 2,6,11.

Macroscopically, diffuse tenosynovial giant cell tumors are large (>5 cm) and are firm and sponge-like. When intra-articular, a villous pattern is usually present, and when extra-articular there are multiple nodular projections. Their color is typically dark brown and heterogeneous with areas of yellow discolouration (xanthoma cells) 11.

See main tenosynovial giant cell tumor article.

On radiographs, features are relatively non-specific with appearances mainly being those of a joint effusion. Bone density and joint space are preserved until the late stages. No calcification is seen. Extrinsic marginal pressure erosions may be present. There may be suggestion of focal areas of soft tissue swelling surrounding the joint +/- dense soft tissues from hemosiderin deposition. 

Joint effusions commonly coexist. The hypertrophic synovium appears as a soft tissue mass, which on account of hemosiderin, may appear slightly hyperdense compared to adjacent muscle. Calcification is very rare in the synovial mass (cf. synovial sarcoma where it is common). Erosions are often well seen on CT.

Typical finding on MRI is extensive synovial proliferation, which may be mass-like, with lobulated or ill-defined margins along with low T1/T2 signal foci due to hemosiderin deposition and/or joint erosions 13.

T2/STIR signal is variable/heterogeneous due to differing amounts of hemosiderin, fat, fluid, fibrous and cellular elements 14.

  • T1: low to intermediate signal

  • T2

    • variable and heterogeneous

    • low to intermediate signal

    • high signal areas may be present, likely due to joint fluid or inflamed synovium

  • STIR: variable and heterogeneous

  • GRE: low and may demonstrate blooming artifact

  • T1 C+ (Gd): variable enhancement

Treatment is with complete synovectomy, which offers a good prospect of cure, provided all the synovium is excised. This can be difficult and therefore adjuvant treatment is often employed, especially external beam radiotherapy which offers excellent control. Intra-articular injection of yttrium-90 is an alternative 12. Recurrence rates are reported to be ~35% (range 7-60%) 2,11.

The differentials include 15:

Cases and figures

  • Figure 1: illustration
  • Figure 2: distribution
  • Case 1: knee
  • Case 2: shoulder
  • Case 3: ankle
  • Case 4: knee
  • Case 5: knee
  • Case 6: knee
  • Case 7: knee
  • Case 8: knee
  • Case 9: temporomandibular joint
  • Case 10: ankle
  • Case 11: ankle
  • Case 12: knee
  • Case 13

Imaging differential diagnosis

  • Ankle joint hematoma
  • Synovial chondromatosis
  • Cyclops lesion / arthrofibrosis
:

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.